Viking Therapeutics, Inc. VKTX
We are a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.
In January 2022, we announced the initiation of a Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735, a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.
In March 2023, we announced the completion of the Phase 1 trial. The study was a randomized, double-blind, placebo-controlled, SAD and MAD study in healthy adults. The primary objectives of the study included evaluation of the safety and tolerability of single and multiple doses of VK2735 delivered subcutaneously and the identification of VK2735 doses suitable for further clinical development. Study investigators also evaluated the pharmacokinetics of single and multiple doses of VK2735. Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D | $345.0M | $101.6M | $63.8M | $54.2M | $45.0M | $31.9M | $23.6M | $19.0M | $13.7M | $9.0M |
| SG&A | $48.4M | $49.3M | $37.0M | $16.1M | $10.7M | $10.7M | $9.1M | $7.1M | $5.3M | $4.8M |
| Total operating expenses | $393.3M | $150.9M | $100.8M | $70.4M | $55.7M | $42.7M | $32.7M | $26.2M | $19.1M | $13.8M |
| Operating income | -$393.3M | -$150.9M | -$100.8M | -$70.4M | -$55.7M | -$42.7M | -$32.7M | -$26.2M | -$19.1M | -$13.8M |
| Pre-tax income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M | -$39.5M | -$25.8M | -$22.1M | -$20.6M | -$14.7M |
| Income tax | $1.0K | $1.0K | $1.0K | $1.0K | $2.0K | $0 | $0 | $0 | $0 | $0 |
| Net income | -$359.6M | -$110.0M | -$85.9M | -$68.9M | -$55.0M | -$39.5M | -$25.8M | -$22.1M | -$20.6M | -$14.7M |
| EPS, basic | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 | — | — | — | — | — |
| EPS, diluted | -3.19 | -1.01 | -0.91 | -0.90 | -0.71 | -0.54 | -0.36 | -0.38 | -0.79 | -0.90 |
| Shares, diluted (wtd. avg.) | $112.7M | $109.0M | $94.3M | $76.8M | $77.2M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $165.8M | $26.7M | $55.5M | $36.6M | $26.4M | $29.1M | $8.4M | $24.8M | $9.0M | $3.1M |
| Short-term investments | $539.9M | $875.9M | $306.6M | $118.9M | $175.7M | $219.3M | $267.3M | $276.7M | $11.6M | — |
| Total current assets | $715.6M | $907.2M | $367.2M | $167.0M | $210.5M | $256.1M | $283.5M | $302.1M | $21.9M | $14.0M |
| Total assets | $715.7M | $908.3M | $368.5M | $168.5M | $210.7M | $256.5M | $284.3M | $302.3M | $22.1M | $14.5M |
| Accounts payable | $53.3M | $9.8M | $7.5M | $8.5M | $1.4M | $4.0M | $2.4M | $959.0K | $1.5M | $1.2M |
| Total current liabilities | $76.7M | $27.4M | $19.1M | $21.9M | $8.8M | $12.1M | $6.8M | $4.5M | $8.7M | $6.5M |
| Total liabilities | $76.7M | $28.0M | $20.1M | $23.2M | $8.8M | $12.2M | $7.1M | $4.6M | $8.7M | $6.5M |
| Retained earnings | -$847.5M | -$487.9M | -$377.9M | -$292.0M | -$223.2M | -$168.2M | -$128.7M | -$102.9M | -$80.9M | -$60.3M |
| Total equity | $639.1M | $880.3M | $348.4M | $145.3M | $201.9M | $244.3M | $277.1M | $297.8M | $13.5M | $8.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$278.7M | -$87.8M | -$73.4M | -$48.4M | -$47.6M | -$21.8M | -$24.8M | -$18.8M | -$14.8M | -$11.1M |
| Stock-based compensation | $40.8M | $29.7M | $16.8M | $8.7M | $6.1M | $5.8M | $3.7M | $2.6M | $1.5M | $1.8M |
| Investing cash flow | $341.4M | -$553.4M | -$179.1M | $54.8M | $38.0M | $41.6M | $7.5M | -$265.7M | -$1.7M | $3.0M |
| Financing cash flow | $76.4M | $612.5M | $271.4M | $4.2M | $6.9M | $950.0K | $887.0K | $300.3M | $22.4M | $10.3M |
| Buybacks | — | — | — | $6.8M | — | — | — | — | — | $229 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-046876.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |